A Study to Evaluate the Safety and Bioequivalence of Mupirocin Calcium Cream, 2% and Bactroban® Cream and Compare Both to a Vehicle in Treatment of Secondarily Infected Traumatic Skin Lesions.

A Double-Blind, Randomized, Parallel-Group, Vehicle-Controlled, Multicenter Study to Evaluate the Safety and Bioequivalence of a Generic Mupirocin Calcium Cream, 2% and Reference Listed Bactroban® Cream (Mupirocin Calcium Cream, 2%) and Compare Both Active Treatments to a Vehicle Control in the Treatment of Secondarily Infected Traumatic Skin Lesions.

The primary objective of this study is to determine the comparability of the safety and efficacy of Mupirocin Calcium Cream, 2% and Bactroban® Cream in subjects with secondarily infected traumatic skin lesions. It will also be determined whether the efficacy of each of the active treatments is superior to that of the vehicle cream (placebo).

Study Overview

• Status: Completed
• Conditions: Secondarily Infected Traumatic Skin Lesions
• Intervention / Treatment: Drug: Mupirocin Calcium Cream, 2%; Drug: Bactroban® Cream; Drug: Cream vehicle of test product

• Study Type: Interventional
• Enrollment (Actual): 1902
• Phase: Phase 1

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 1 year and older (Child, Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Healthy male or nonpregnant females aged 18 months or older with a secondarily infected traumatic skin lesion such as a laceration, sutured wound, or abrasion.
• The laceration or sutured wound should not exceed 10 cm in length with surrounding erythema not more than 2 cm from the edge of the lesion. An abrasion should not exceed 100 cm2 in total area with surrounding erythema not more than 2 cm from the edge of the abrasion.
• Positive baseline culture for S. aureus and/or S. pyogenes from a sample taken from the secondarily infected traumatic skin lesion.
• Positive Gram stain or Wright stain for confirmation of white blood cells in the pus/exudate from the secondarily infected traumatic skin lesion.
• Skin Infection Rating Scale total score for the secondarily infected traumatic skin lesion of at least 8 at baseline.
• Women of childbearing potential, in addition to having a negative urine pregnancy test, must be willing to use an acceptable form of birth control during the study. Subjects entering the study who are on hormonal contraceptives must have been on the method for at least 90 days prior to the study and continue the method for the duration of the study. Subjects who had used hormonal contraception and stopped must have stopped no less than 90 days prior to the study.
• Subjects 18 years of age or older must provide Institutional Review Board approved written informed consent. Subjects under the age of 18 years must have parent or legal guardian provide Institutional Review Board approved written consent. An assent form for minors must be completed for subjects under the legal age of consent, depending on the age range required by state laws.
• Subjects must be willing and able to understand and comply with the requirements of the study, apply the medication as instructed, return for the required study visits, comply with therapy prohibitions, and be able to complete the study.
• Subjects must be in good health and free from any clinically significant disease, other than secondarily infected traumatic skin lesions, that might interfere with the study evaluations.

Exclusion Criteria:

• Subjects who are pregnant, nursing, or planning a pregnancy within the study participation period.
• Any dermatological disorder that may interfere with evaluation of the subject's secondarily infected traumatic skin lesion(s).
• Bacterial skin infection that, because of depth or severity, could not be appropriately treated with a topical antibiotic.
• Secondarily infected bite or puncture wound.
• Systemic signs or symptoms of infection.
• Requirement for surgical intervention for treatment of the infection prior to study entry.
• A subject must not have received any topical corticosteroid, topical antibiotic, or antifungal agent for at least 48 hours (2 days) prior to baseline.
• A subject must not have received any systemic antibiotic or systemic corticosteroid for at least 7 days prior to baseline.
• Primary or secondary immunodeficiency.
• Diabetes.
• Presence of any other medical condition that might adversely affect the safety of the study participants or confound the study results.
• History of hypersensitivity or allergy to mupirocin and/or any of the study medication ingredients.
• Subjects who consume excessive amounts of alcohol, abuse drugs, or have any condition that would compromise compliance with the protocol.
• Treatment with an investigational drug or device within 30 days prior to study entry.
• Previously enrollment in this study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Mupirocin Calcium Cream, 2%; Mupirocin Calcium Cream, 2% (Taro Pharmaceuticals Inc.)	Drug: Mupirocin Calcium Cream, 2%; Mupirocin Calcium Cream, 2% (Taro Pharmaceuticals Inc.) applied topically 3 times per day for 10 consecutive days.
Active Comparator: Bactroban® Cream; Bactroban® Cream (mupirocin calcium cream, 2%) (GlaxoSmithKline)	Drug: Bactroban® Cream; Bactroban® Cream (mupirocin calcium cream, 2%) (GlaxoSmithKline) applied topically 3 times per day for 10 consecutive days.
Placebo Comparator: Cream vehicle of test product; Cream vehicle of test product (Taro Pharmaceuticals Inc.)	Drug: Cream vehicle of test product; Cream vehicle of test product (Taro Pharmaceuticals Inc.) applied topically 3 times per day for 10 consecutive days.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Clinical cure at visit 4	The proportion of subjects in each treatment group with clinical cure, defined as an SIRS score of 0 for all signs and symptoms at Visit 4/Follow-up (7 days after the end of treatment).	7 days after end of treatment

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Clinical cure at visit 3	The proportion of subjects with clinical cure at Visit 3/End of Treatment.	Day 10 (visit 3)
Bacteriological cure at visit 3	The proportion of subjects with bacteriological cure, defined as elimination of S.aureus and S. pyogenes or response was such that no culture material was available and therefore evidence of pathogen eradication, at Visit 3/End of Treatment.	Day 10 (visit 3)
Bacteriological cure at visit 4	Proportion of subjects with bacteriological cure at Visit 4/Follow-up.	7 days after end of treatment

Collaborators and Investigators

• Sponsor: Taro Pharmaceuticals USA
• Investigators: Study Chair: Symbio CRO, http://symbioresearch.com; Study Chair: Catawba Research, LLC, https://catawbaresearch.com/

Study record dates

Study Major Dates

• Study Start: February 1, 2013
• Primary Completion (Actual): February 1, 2014
• Study Completion (Actual): May 6, 2019

Study Registration Dates

• First Submitted: June 10, 2013
• First Submitted That Met QC Criteria: June 10, 2013
• First Posted (Estimate): June 12, 2013

Study Record Updates

• Last Update Posted (Actual): May 9, 2019
• Last Update Submitted That Met QC Criteria: May 8, 2019
• Last Verified: May 1, 2019

More Information

Terms related to this study

• Keywords: Mupirocin Calcium Cream 2%; Bactroban® Cream; Secondarily infected traumatic skin lesions
• Additional Relevant MeSH Terms: Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Anti-Infective Agents; Enzyme Inhibitors; Anti-Bacterial Agents; Protein Synthesis Inhibitors; Calcium-Regulating Hormones and Agents; Calcium; Mupirocin
• Other Study ID Numbers: MUPC 1106/1305